Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in de novo diffuse large B-cell lymphoma: a multicenter retrospective study

被引：0

作者：

Kim, Yu Ri ^{[1
]}

Shin, Ho Jin ^{[2
]}

Yhim, Ho-Young ^{[3
]}

Yang, Deok-Hwan ^{[4
]}

Park, Yong ^{[5
]}

Lee, Ji Hyun ^{[6
]}

Lee, Won-Sik ^{[7
]}

Do, Young Rok ^{[8
]}

Mun, Yeung-Chul ^{[9
]}

Kim, Dae Sik ^{[10
]}

Kim, Jin Seok ^{[11
]}

机构：

[1] Yonsei Univ, Gangnam Severance Hosp, Dept Internal Med, Div Hematol,Coll Med, Seoul, South Korea

[2] Pusan Natl Univ, Dept Internal Med, Div Haematol Oncol, Sch Med, Busan, South Korea

[3] Jeonbuk Natl Univ, Med Sch, Div Haematol Oncol, Dept Internal Med, Jeonju, South Korea

[4] Chonnam Natl Univ, Dept Internal Med, Div Haematol Oncol, Hwasun Hosp, Gwangju, Jeollanam Do, South Korea

[5] Korea Univ, Dept Internal Med, Div Hematol Oncol, Anam Hosp, Seoul, South Korea

[6] Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea

[7] Inje Univ, Dept Internal Med, Div Haematol Oncol, Busan Paik Hosp, Busan, South Korea

[8] Keimyung Univ, Dongsan Med Ctr, Dept Internal Med, Div Hematooncol, Daegu, South Korea

[9] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[10] Korea Univ, Guro Hosp, Div Hematol Oncol, Dept Internal Med, Seoul, South Korea

[11] Yonsei Univ, Coll Med, Div Hematol, Severance Hosp,Dept Internal Med, Seoul, South Korea

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

基金：

新加坡国家研究基金会;

关键词：

diffuse large B-cell lymphoma; bone marrow involvement; immunoglobulin gene rearrangement; progression-free survival; transplantation; NON-HODGKINS-LYMPHOMA; PROGNOSTIC-SIGNIFICANCE; RESPONSE ASSESSMENT; RITUXIMAB; CHOP; CLASSIFICATION; INFILTRATION; CHEMOTHERAPY; CONCORDANT; DIAGNOSIS;

D O I：

10.3389/fonc.2024.1363385

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

<bold>Background: </bold>Bone marrow (BM) involvement is an indicator of a poor prognosis in diffuse large B-cell lymphoma (DLBCL); however, few studies have evaluated the role of immunoglobulin gene rearrangement (IgR) in detecting BM involvement. <bold>Methods: </bold>We evaluated the clinical characteristics and treatment outcomes of patients with DLBCL based on histological BM involvement or positive BM IgR using polymerase chain reaction or next-generation sequencing. We also investigated the role of consolidative upfront autologous hematopoietic stem cell transplantation (ASCT) in patients with DLBCL and BM involvement. <bold>Results: </bold>Among 624 patients, 123 (19.7%) with histological BM involvement and 88 (17.5%) with positive IgR in histologically negative BM had more advanced disease characteristics. Overall (OS) and progression-free (PFS) survival was better for patients with negative BM histology and negative IgR than that in patients with histological BM involvement (P = 0.050 and P < 0.001, respectively) and positive IgR with negative BM histology (P = 0.001 and P = 0.005, respectively). Survival rates did not differ among 82 (13.1%) patients who were treated with upfront ASCT and had histological BM involvement or positive IgR with negative BM histology. The survival outcomes were worse for patients who were not treated with upfront ASCT and for those with histological BM involvement or positive IgR, than for those with negative BM histology and negative IgR. <bold>Conclusion: </bold>Patients diagnosed with DLBCL and BM involvement based on histology or IgR had aggressive clinical features and poor survival. Upfront ASCT mitigated poor prognosis due to BM involvement.

引用

页数：9

共 29 条

[1] Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma [J].